InspireMD Expands With New Miami Headquarters
Express News | InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the Cguard Prime Carotid Stent System
InspireMD Inc (NSPR) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges
InspireMD Wins FDA IDE for Carotid Stent Study
InspireMD Advances With FDA Study Approval and Global Goals
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
InspireMD Launches 2024 Plan to Attract Talent With Stock
InspireMD Analyst Ratings
Piper Sandler Maintains InspireMD(NSPR.US) With Buy Rating, Raises Target Price to $4.5
Piper Sandler analyst Adam Maeder maintains $InspireMD(NSPR.US)$ with a buy rating, and adjusts the target price from $3.5 to $4.5.According to TipRanks data, the analyst has a success rate of 60.8%
InspireMD (NSPR) Receives a Buy From Piper Sandler
InspireMD Submits Carotid Stent for FDA Premarket Approval
Express News | InspireMD Inc - U.S. Commercial Launch Anticipated in H1 2025 if Approved
Express News | InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the Cguard™ Prime Carotid Stent System
Investors in InspireMD (NASDAQ:NSPR) Have Unfortunately Lost 88% Over the Last Five Years
Earnings Call Summary | InspireMD(NSPR.US) Q2 2024 Earnings Conference
InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript
Companies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In Growth
Earnings Flash (NSPR) INSPIREMD Reports Q2 Revenue $1.7M, Vs. Street Est of $1.7M
Express News | InspireMD Q2 Revenue USD 1.739 Million
Express News | InspireMD Q2 Income From Operations USD -8.26 Million